Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;40(8):751-776.
doi: 10.1007/s40273-022-01140-y. Epub 2022 Jul 5.

The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review

Michal Witkowski  1 , Søren Ilsøe Moreno  2 , João Fernandes  2 , Pierre Johansen  3 , Margarida Augusto  4 , Sunita Nair  5
Affiliations

The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review

Michal Witkowski et al. Pharmacoeconomics. 2022 Aug.

Abstract

Background: The global prevalence of non-alcoholic steatohepatitis (NASH) is increasing, such that NASH is predicted to become the leading cause of liver transplantation (LT) in the US by 2025. Despite this, data on the economic burden of NASH are limited.

Objectives: This systematic literature review aimed to summarise and critically evaluate studies reporting on the economic burden of NASH and identify evidence gaps for subsequent research.

Methods: Medline, EMBASE, the Cochrane Library and EconLit were searched up to 6 January 2021 for English language articles published from January 2010 to January 2021 inclusive that reported economic outcomes of a NASH population or subpopulation. Evidence was presented and synthesised using narrative data analysis, and quality was assessed by two reviewers using an 11-item checklist developed for economic evaluations and adapted to cost of illness.

Results: Fourteen studies were included, of which five presented data on costs and resource use, four on costs only and five on resource use only. Overall, NASH is associated with a significant and increasing economic burden in terms of healthcare resource utilisation (HCRU) and direct and indirect costs. This burden was higher among NASH patients with advanced (fibrosis stage 3-4) versus early (fibrosis stage 0-2) disease, symptomatic versus asymptomatic disease and for patients with complications or comorbidities versus those without. In LT patients, those with NASH as the primary indication had greater HCRU and higher costs compared with non-NASH indications such as hepatitis B and C viruses. Considerable variability in HCRU and costs was seen across the US and Europe, with the highest costs seen in the US. The quality of the included studies was variable, and the studies themselves were heterogeneous in terms of study methodology, patient populations, comorbidities, follow-up time and outcomes measured.

Conclusions: This review highlights a general scarcity of NASH-specific economic outcomes data. Despite this, the identified studies show that NASH is associated with a significant economic burden in terms of increased HCRU, and high direct medical and non-medical costs and societal burden that increases with disease severity or when patients have complications or comorbidity. More national-level NASH prevalence data are needed to generate accurate forecasts of HCRU and costs in the coming decades.

Funding: Novo Nordisk A/S, Søborg, Denmark.

Plain language summary

It is important to know the cost of treating different diseases because this helps to guide how healthcare resources and funds are used. Non-alcoholic steatohepatitis (NASH) is a serious liver disease that can lead to liver scarring (cirrhosis), liver transplantation and early death, and the number of people with NASH is growing around the world. Fourteen studies published over the past 10 years have investigated the costs of treating patients with NASH. Patients with NASH generally use more healthcare services with a higher cost than the general population or patients with type 2 diabetes. In people with more serious liver disease, such as liver transplant patients, NASH tends to be more expensive and use more healthcare services than other serious liver diseases such as hepatitis. Costs and use of health services are particularly high in patients with more severe NASH, or those who have other diseases or complications in addition to NASH (such as type 2 diabetes or kidney failure).

PubMed Disclaimer

Conflict of interest statement

SIM, PJ and MA are employees of Novo Nordisk A/S or Novo Nordisk Denmark A/S, and JF was formerly an employee of Novo Nordisk A/S. SIM, PJ, MA and JF are also shareholders of Novo Nordisk A/S. MW and SN are employees of DRG Abacus (Clarivate), who were commissioned to perform this systematic literature review by Novo Nordisk A/S.

Figures

Fig. 1
Fig. 1
Flow diagram of publications included and excluded from systematic review. e1 excluded studies after title/abstract screening stage, e2 excluded studies after full-text review stage, i1 studies to screen at title/abstract stage, i2 studies to screen at full-text review stage, i3 included studies after full-text review stage
See this image and copyright information in PMC

References

    1. Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22(1):11–21. doi: 10.1016/j.cld.2017.08.003. - DOI - PMC - PubMed
    1. Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, Lebensztejn DM. From nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD)-new terminology in pediatric patients as a step in good scientific direction? J Clin Med. 2021;10(5):924. doi: 10.3390/jcm10050924. - DOI - PMC - PubMed
    1. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69(3):564–568. doi: 10.1136/gutjnl-2019-318813. - DOI - PubMed
    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530. doi: 10.1016/S0140-6736(16)00618-8. - DOI - PMC - PubMed
    1. NCD Risk Factor Collaboration (NCD-RisC) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387(10026):1377–1396. doi: 10.1016/S0140-6736(16)30054-X. - DOI - PMC - PubMed

Publication types